Jeuveau is a neurotoxin developed from Evolus, a South Korean company. Juveau works similar to Botox. It is injected into the muscle to prevent the appearance of wrinkles by blocking the nerve impulses that control muscle contraction. Jeuveau is the latest of the neurotoxins to achieve FDA approval in February 2019. Unlike the previous 3 neurotoxins, it is only FDA approved for cosmetic reasons and is not approved for medical management of hyperhydrosis or migraines.